Picture of DSM-Firmenich AG logo

DSFIR — DSM-Firmenich AG News Story

0.000.00%
nl flag iconLast trade - 00:00
IndustrialsBalancedLarge Cap

Dsm-firmenich narrows down core profit guidance on FX uncertainty (updated)

Adds CEO quote paragraph 5, earnings details paragraph 4,6,7,8

By Dimitri  Rhodes

July 31 (Reuters) - European chemicals maker dsm-firmenich DSFIR.AS on Thursday narrowed down its 2025 adjusted core profit guidance, citing unfavorable foreign exchange effects.

The group now expects adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to reach 2.4 billion euros ($2.74 billion), compared to a previous estimate of at least 2.4 billion euros.

"In the underlying core business, nothing has changed, but FX obviously we can't control," CEO Dimitri de Vreeze told Reuters, adding he sees continued uncertainty in the second half.

Dsm-firmenich, whose products are used in perfumes made by French luxury groups LVMH LVMH.PA and Kering PRTP.PA, said its adjusted core profit came in at 610 million euros. That beat  analysts' average forecast of 513 million euros in a company-compiled consensus.

"It's like a duck that's nicely floating, but there's a lot of hard work underneath to keep it moving that you don't see, but here we see a relatively good duck in good order for the first half, and we're confident for the second half," the CEO told Reuters.

    In February, the company sold its stake in a joint enzymes venture to Danish group Novonesis NSISb.CO for 1.5 billion euros as part of a strategic revamp aimed at sharpening its focus on core businesses like perfumes and flavours.

It said last year it was planning to carve out its animal health and nutrition unit by the end of 2025, which would lower its exposure to earnings volatility in the vitamins segment.

The unit reported a 293% year-on-year adjusted EBITDA jump to 342 million euros in the first half, supported by temporary vitamin price effects.

($1 = 0.8744 euros)

 (Reporting by Dimitri  Rhodes; Editing by Matt Scuffham)

 ((Dimitri.Rhodes@thomsonreuters.com;))

Recent news on DSM-Firmenich AG

See all news